Description
SS-31 10mg (also known as Elamipretide, Bendavia, or MTP-131) is a first-in-class synthetic tetrapeptide designed to target mitochondrial dysfunction. It is a highly selective mitochondrial-targeted antioxidant that penetrates cell membranes and localizes to the inner mitochondrial membrane. Unlike traditional antioxidants, SS-31 binds specifically to cardiolipin, a unique phospholipid essential for the structural integrity of the mitochondrial cristae and the efficiency of the electron transport chain. In September 2025, the FDA granted accelerated approval for Elamipretide (marketed as Forzinity) for the treatment of Barth syndrome, marking a major milestone in mitochondrial medicine.
Benefits
Mitochondrial Membrane Stabilization: SS-31 binds to cardiolipin, preventing its oxidation and maintaining the structural integrity of the mitochondrial inner membrane.
Enhanced ATP Production: By optimizing the organization of the respiratory chain supercomplexes, it improves the efficiency of cellular energy production.
Reduction of Oxidative Stress: It significantly lowers the production of reactive oxygen species (ROS) at the source, protecting cells from oxidative damage without interfering with normal signaling.
Cardioprotective Effects: Research has shown it can improve cardiac function, reduce infarct size in ischemia models, and support heart health in conditions like Barth syndrome and heart failure.
Neuroprotection: SS-31 has demonstrated the potential to protect neurons, improve synaptic plasticity, and mitigate cognitive decline in models of Alzheimer’s disease and traumatic brain injury.
Improved Muscle Strength and Recovery: It has been shown to enhance exercise tolerance and muscle fiber energetics, particularly in aging or diseased skeletal muscle.
Renal Support: Studies indicate it can protect against acute kidney injury and chronic kidney disease by reducing mitochondrial damage in renal tubular cells.
Vision Preservation: It is currently being investigated for its ability to slow the progression of dry age-related macular degeneration (AMD) by protecting retinal mitochondria.
Anti-Inflammatory Properties: By inhibiting the NLRP3 inflammasome and reducing mitochondrial “leakage,” it helps suppress chronic systemic inflammation.
Longevity and Healthspan Extension: By addressing the “mitochondrial theory of aging,” SS-31 is a primary candidate in research aimed at reversing age-related cellular decline.
Conclusion
SS-31 represents a breakthrough in treating conditions rooted in bioenergetic failure. While its approval for Barth syndrome is a significant step, its applications in broader areas like neurodegeneration, cardiovascular health, and general aging are still under intensive clinical and academic investigation. As with all research-grade peptides, individual subject results may vary, and continued clinical validation is necessary.
Disclaimer
Disclaimer: The information provided is intended solely for research and educational purposes. It is not meant as medical advice, nor should it be used for diagnosis, treatment, prevention, or cure of any disease or health condition. This is a research chemical and is not approved for human use by the FDA or any other regulatory body. Its safety and efficacy for human use have not been established. Users are advised to conduct thorough research and consult with qualified healthcare professionals before considering its use. All experimentation should be conducted in accordance with relevant laws, regulations, and ethical guidelines.
